BRIEF-Nicox unveils positive Phase III results for eye drug
Sept 25 (Reuters) - Nicox :
* Nicox and Valeant Pharmaceuticals announce positive top-line results from pivotal phase 3 studies conducted with Vesneo (latanoprostene bunod)
* Says studies met their primary endpoint and showed positive results on a number of secondary endpoints
* Says product has peak sales potential of around $500 million+ in U.S. and over $1 billion globally
* Says Bausch + Lomb expects to submit a new drug application to the FDA for approval of Vesneo in mid-2015 Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.